E3 PreliminaryPreliminaryPEM unclearMechanisticPeer-reviewedMachine draft
Differential-display PCR of peripheral blood for biomarker discovery in chronic fatigue syndrome.
Steinau, Martin, Unger, Elizabeth R, Vernon, Suzanne D et al. · Journal of molecular medicine (Berlin, Germany) · 2004 · DOI
Quick Summary
Researchers looked at immune cells from one ME/CFS patient and one healthy person to find differences in which genes were turned on or off. They found about 10 genes that behaved differently between the two people, with most differences present even before exercise. Many of these genes are involved in immune function, suggesting that ME/CFS may involve problems with how the immune system works.
Why It Matters
This study identifies specific immune-related genes that may be abnormal in ME/CFS, potentially explaining the immune dysfunction many patients experience. The development of assays for these biomarkers could eventually help doctors identify and understand ME/CFS through blood tests rather than clinical judgment alone.
Observed Findings
- Five genes were downregulated in the CFS subject: cystatin F, MHC class II, platelet factor 4, fetal brain EST, and perforin
- Five genes were upregulated in the CFS subject: cathepsin B, DNA polymerase epsilon4, EST PBMC191MSt, heparanase precursor, and ORF2/L1 element
- Eighty-six percent of gene expression differences between the CFS subject and control were present at baseline before exercise challenge
- Of 95 nonredundant sequences identified, 50 matched known genes, 38 matched genes of unknown function, and 7 had no database matches
Inferred Conclusions
- Gene expression patterns in peripheral blood mononuclear cells differ between ME/CFS patients and healthy controls, with most differences present at baseline
- Many differentially expressed genes have known roles in immune function and defense, supporting the hypothesis of immune dysregulation in ME/CFS pathogenesis
- Differential-display PCR is a useful method for discovering candidate biomarkers in ME/CFS that warrant validation in larger studies
Remaining Questions
- Are these gene expression differences present across the broader ME/CFS patient population, or are they specific to this individual?
- Do these gene expression abnormalities correlate with ME/CFS symptom severity, duration, or other clinical features?
What This Study Does Not Prove
This study does not prove that these gene expression differences cause ME/CFS or that they are present in all ME/CFS patients—it is a case study of one person compared to one control. The findings cannot yet distinguish whether these differences are characteristic of ME/CFS, correlate with symptom severity, or represent disease biomarkers without validation in larger patient populations.
Tags
Biomarker:Gene ExpressionBlood Biomarker
Method Flag:No ControlsSmall SampleExploratory Only
Metadata
- DOI
- 10.1007/s00109-004-0586-4
- PMID
- 15490094
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →